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Introduction
In this case study, we report a remarkable systemic response
after treatment with electrochemotherapy and calcium electro-
poration in a patient with disseminated malignant melanoma.
Electrochemotherapy is an evolving cancer treatment, a
non-thermal event where high voltage pulses permeabilize
cell membranes in tumor masses and dramatically enhance
uptake and cytotoxicity of chemotherapeutic agents.
Electrochemotherapy with bleomycin is regularly used for
cutaneous and subcutaneous metastases and is an effective
treatment with a described high local response in malignant
melanomas, and carcinomas [1–7].
Preclinical reports have shown that electrochemotherapy
not only possesses the ability to exert a cytotoxic effect on can-
cer cells, but also has the capability to generate an anticancer
immune response, as it induces an immunogenic cell death
with release of antigens from the cytosol and antigen presenta-
tion on the cell membrane thereby alerting the immune sys-
tem [8]. Preclinical studies have demonstrated that the local
effect of electrochemotherapy is reduced in immunodeficient
mice, with lack of T lymphocytes [8,9]. On the contrary, adding
interleukin-2 or other pro-inflammatory cytokines has a syner-
gistic effect enhancing the response of electrochemotherapy
on both local and distant tumors [10–12]. This indicates that in
addition to the local cytotoxic effect from bleomycin, an
immune response also plays a part in the effect of electroche-
motherapy. Nevertheless electrochemotherapy alone has so far
not been reported to be able to exert a treatment effect out-
side the treatment area [1,13,14].
Here, we present a case with clinically evident and biopsy-
verified response in both treated and untreated malignant
melanoma lesions, showing that electrochemotherapy and
calcium electroporation may in fact give rise to a systemic
immune response. This is of particular interest as electroche-
motherapy is now being investigated in combination with
checkpoint inhibitors [15,16]. This case indicates that
electrochemotherapy and maybe calcium electroporation
could have a role as immune activator and may be consid-
ered in combination with immunotherapeutic treatments.
Case report
An 85-year-old woman with a previous medical history of
myxedema and osteoarthritis, but otherwise well, was diag-
nosed in 2013 with malignant melanoma on her left heel.
Pathology showed acral lentiginous melanoma, with a thick-
ness of 7.3mm, Clarks level 5, with ulceration and dermal
mitosis, BRAF mutation negative. She underwent surgery to a
2 cm free margin and had two sentinel nodes removed both
with parenchymatous metastases. Inguinal lymph node resec-
tion and PET-CT scan did not show any additional sign of dis-
semination. However, the PET-CT scan revealed pulmonary
embolism and a neuroendocrine tumor in her uterus.
Five months after her initial diagnosis of malignant melan-
oma she relapsed with cutaneous metastases on her left lower
limb and two pathologically enlarged lymph nodes in the left
inguinal region and pelvis. She was assessed ineligible for iso-
lated limb perfusion (ILP) due to her comorbidities and anti-
coagulant treatment. In June 2014, she started chemotherapy
with temozolamide (standard dose). She tolerated the treat-
ment poorly despite a reduction to 50% dose, and the treat-
ment was discontinued after two series due to pancytopenia,
infection and thrombus in her arm. The patient was deemed
ineligible for ipilumumab and all treatments were stopped.
After six months without any treatment, she was referred
for electrochemotherapy. At the time she had a large number
of cutaneous metastases on her left lower limb, extending
from above the ligament level to the lower leg, both lateral,
medial and anteriorly, with several ulcerated and bleeding
lesions (Figure 1). The two enlarged lymph nodes in the
inguinal region and pelvis had shown some regression after
treatment with temozolamide, but were still pathologically
CONTACT Julie Gehl karen.julie.gehl@regionh.dk Department of Oncology, Herlev and Gentofte Hospital, Center for Experimental Drug and Gene
Electrotransfer (CEDGE), University of Copenhagen, Herlev Ringvej 75, 2730 Herlev, Denmark
Supplemental data for this article can be accessed here.
 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in
any way.
1126 LETTERS TO THE EDITOR
enlarged. She was treated with electrochemotherapy in gen-
eral anesthesia according to European Standard Operating
Procedures of Electrochemotherapy (ESOPE) [17]. The dose of
bleomycin (Baxter A/S, Søborg, Denmark) was 24,000 IE and
more than 100 lesions were treated with a total of 407 pulse
sequences, applied with hexagonal needle electrodes
Figure 1. Images of left thigh and left calf, over time. (A) February 2015, before electrochemotherapy. Cutaneous metastases extended from the left side of the abdo-
men to the left calf, with bleeding lesions. (B) March 2015, the day after treatment with electrochemotherapy. The treated areas include the front and back of her thigh,
20 25 cm and 30 13 cm, respectively, and on the back of her calf 20 10 cm. The areas are marked with pen and appear erythematous. The bleeding has stopped
and the metastases appear pale. (C) May 2015, two months after treatment with electrochemotherapy, leveling of the cutaneous metastases in the treated area, the
lesions appear more pale and as scars, from where exophytic lesions have fallen off, are visible. (D) July 2016, 12 months after retreatment with calcium and electropor-
ation and 16 months after the first electrochemotherapy, complete leveling of all cutaneous metastases and appearance of vitiligo in both treated and untreated area.
Biopsies from pigmented lesions were without malignancy (see supplementary Figure 1).
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(Cliniporator, IGEA, Carpi, Italy). Pulses were delivered to the
front and back of her thigh, 20 25 cm and 30 13 cm,
respectively, and on the back of her calf 20 10 cm
(Figure 1). She underwent one treatment only, and due to
the considerable number of lesions, mainly lesions that cre-
ated discomfort for the patients were treated, the rest of the
cutaneous metastases and the lymph nodes remained
untreated. The only reported adverse advents were fever the
night after treatment and an increase in pain from NRS 7 to
NRS 9 (Numerical Rating Scale of pain where 0¼no pain and
10¼ severe pain). Already one day after treatment, the bleed-
ing was reduced and the treated lesions appeared pale. In
the months after treatment, the treated metastases became
necrotic and decreased in size.
Four months after electrochemotherapy, she had clinical
progression in the surrounding skin, despite the continued
improvement in the treated area. Two new metastases on
the back of her thigh appeared, as well as a new lesion on
her back. The latter was surgically removed and the path-
ology showed an almost complete regression of a heavily
pigmented lesion, with dense lymphocytotic infiltration with
predominance of T cells and plasma cells.
Prior treatments had been harsh for the patient, therefore,
she only wanted treatment of two recently progressed meta-
stases on the back of her thigh, while the rest of the lesions,
which had not previously received electrochemotherapy, still
remained untreated. She was treated according to an experi-
mental protocol comparing calcium electroporation with
electrochemotherapy with bleomycin. The treatment was car-
ried out with intratumoral injection of 0.39ml bleomycin
1000 IE/ml in metastasis number 1 and 0.27ml calcium chlor-
ide (Amgros I/S, København Ø, Denmark) 9mg/ml in metasta-
sis number 2. The injected volumes were calculated
according to ESOPE [17]. Injections of the drugs were imme-
diately followed by a total of eight electric pulse sequences.
Both metastases had complete response, verified with biop-
sies 6 months after the treatment. Nine months after retreat-
ment, the patient had strikingly smooth skin with complete
leveling of all the cutaneous metastases. Clinically, the skin
lesions had the appearance of regressing melanoma metasta-
ses with a completely flat texture and fading pigmentation.
There were no new lesions. Vitiligo had developed around
the treated as well as untreated lesions on the left lower
limb and on both forearms and her right cheek (Figure 2).
Objectively, the patient had recovered with improved per-
formance status, she had gained 10 kg in bodyweight, her
analgesic treatment was reduced and she reported signifi-
cantly improved quality of life.
The PET-CT scan, 12 months after retreatment (July 2016),
showed no signs of the previous enlarged lymph node in the
inguinal region, and the lymph node in pelvis appeared nec-
rotic but had a minimal PET positive spot (Figure 3). The lat-
ter was biopsied and showed necrosis with melanophages.
Within the same month, biopsies from pigmented skin
lesions in the treated and untreated areas were collected.
Biopsies from both areas showed discrete chronic inflamma-
tion with no signs of malignant melanoma and a large
amount of melanophages in the biopsy from treated area
(Supplementary Figure 1).
After the retreatment, she received no treatment for her
malignant melanoma, but after 17 months her malignant
melanoma recurred with a new subcutaneous metastasis on
her lower limb and several brain metastases and she under-
went irradiation.
Discussion
This patient demonstrated a remarkable response to electro-
chemotherapy, with biopsy verified complete remission in
both treated and untreated cutaneous metastases as well as
radiological remission of an inguinal lymph node metastasis.
This phenomenon has not been reported before in patients
with malignant melanoma after electrochemotherapy alone.
The reason this case is different from those previously
described is unknown, but the following hypotheses can be
discussed.
1. Unlike previously reported cases, the treatment area was
extensive including more than a hundred lesions, which
Figure 2. July 2016. Illustration of widespread vitiligo in treated and untreated
areas. (A) Vitiligo in distant untreated area. (B–D) Vitiligo extends beyond the
actual treated area.
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may have released large amounts of cancer antigens as
well as danger signals, activating the immune response
to an extent that generated a systemic response.
2. It is also possible that the first major treatment created a
strong immune memory and was activated by the
retreatment with electrochemotherapy and calcium elec-
troporation 4 months later, creating a significant sys-
temic response.
Spontaneous remission is well known in patients with
malignant melanoma. It is most commonly seen in primary
lesions, but in a subset of patients with disseminated disease,
spontaneous remission has been reported at a frequency of
0.23% [18]. In this case, the patient presented with rampant
progression with hundreds of cutaneous metastases up to
the time of her first treatment with electrochemotherapy.
The ability of electrochemotherapy to generate immune
responses has already been reported from preclinical studies
[8,19,20]. We know that electroporation alone has a weak
immunogenic effect with release of antigens, which can be
strengthened by the addition of bleomycin. It has been
shown in murine studies that electrochemotherapy generates
cytotoxic T-lymphocytes specific for the treated cancer type,
and is able to generate a protective immune memory pre-
venting the growth of tumors when exposed to the
same tumor type [8,19,20]. Interestingly, a recent study in
patients treated with electrochemotherapy for malignant
melanoma showed an increased presence of calrecticulin,
which is associated with immunogenic cell death.
Furthermore, an increase in the presence of cytotoxic T-cells
alongside a decrease in the presence of regulatory T-cells,
was observed when comparing post-treatment to pretreat-
ment biopsies [21].
Several observations in this case indicate immunological
involvement outside the treated area. Four months after her
first extensive treatment and before retreatment, the biopsy
Figure 3. PET-CT scans and CT-scans before and after treatment. (A) September 2014, before treatment with electrochemotherapy. (A1) MIP image (maximum
intensity projection), showing the two metastases. (A2) PET/CT scan shows an enlarged lymph node in the left inguinal region measuring 2.7 cm. (A3) An enlarged
necrotic lymph node in the left side of pelvis measuring 2.4 cm. (B) July 2016, 16 months after electrochemotherapy and 12 months after retreatment with calcium
electroporation and electrochemotherapy. (B1) MIP image shows disappearance of lymph node in the left inguinal region. (B2) PET/CT scan shows disappearance of
lymph node in left inguinal region. (B3) Lymph node in left pelvis is almost completely necrotic, and cannot be measured. This inguinal node was subsequently
biopsied and there was no sign of malignancy. Of note, a new PET/CT-scanner was employed for the second scan, thus direct comparison of the SUV values is not
strictly possible.
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from the tumor on her back showed almost complete regres-
sion with infiltration of T-lymphocytes and plasma cells.
Furthermore biopsies from both treated and untreated
lesions on her left lower limb, collected 16 months after her
first treatment and 12 months after retreatment, showed
complete regression and inflammation, and infiltration of
melanophages was seen in the lesions from the treated area
(Supplementary Figure 1). In addition, vitiligo appeared
around treated as well as untreated lesions and appeared on
her forearms and face (Figure 2). Vitiligo is often reported in
advanced metastatic melanoma patients treated with
immune-based therapies [22,23] and is associated with an
improved clinical response.
The patient was retreated with both calcium electropor-
ation and electrochemotherapy. Calcium electroporation is a
novel anticancer treatment where calcium is internalized in
cancer cells by electroporation, which leads to acute cell
death with ATP depletion and necrosis [24,25]. Preclinical
data with calcium electroporation on colon tumor bearing
mice have shown to generate a pro-inflammatory cytokine
response and a protective immune memory (manuscript sub-
mitted). Whether calcium electroporation could have contrib-
uted to a reactivation of the immune system in this case is
unknown.
Electrochemotherapy is an evolving treatment included in
national guidelines, e.g., from NICE (National Institute of
Health and Clinical Excellence, UK) [26] and is in several
guidelines in treatment of malignant melanoma, cutaneous
metastases of any histology, and several clinical trials with
electrochemotherapy for internal tumors are progressing.
This case represents a new, very interesting perspective to
electrochemotherapy as an activator of the immune system
with an approach to not only treat local but also distant
tumors. Several clinical data on combination of electroche-
motherapy and checkpoint inhibitors are emerging [15,16]
and show that the combination is feasible with systemic
responses, although randomized controlled trials would be
needed to determine the possible presence of a synergistic
effect.
It also demonstrates how electrochemotherapy is a suit-
able treatment for fragile, elderly patients. In this case, the
patient was 83 years old at diagnosis and had developed
extensive disease. Due to comorbidity, she was ineligible for
ILP and did not tolerate chemotherapy very well. When
referred for electrochemotherapy, her general condition was
poor, but her toleration of the treatment was acceptable,
with minimal hospitalization (4 days).
With these advantages, electrochemotherapy, and possibly
calcium electroporation, would be interesting suggestions in
combination with immunostimulating agents for a strategy
to enhance response and improve survival in patients with
disseminated malignant melanoma.
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Impact of assumptions – the example of the Welch-analysis of mammography
screening effectiveness
Elsebeth Lynge, Anna-Belle Beau and Søren Lophaven
Department of Public Health, University of Copenhagen, Copenhagen, Denmark
Introduction
Based on analysis of SEER data from 1975 to 2012, Welch
et al. [1] concluded that in screening, women were more
likely to have breast cancer detected ‘that was overdiag-
nosed than to have earlier detection of a tumor that was
destined to become large’, and that ‘the reduction in breast
cancer mortality after the implementation of screening was
predominantly the result of improved systemic therapy.’
Welch assumptions
The Welch et al. analysis builds on a number of assumptions
that might not be unproblematic.
First, it was assumed ‘that the underlying probability that
clinically meaningful breast cancer would develop was stable’
over time given no screening. This assumption was based on
the observed, very low and stable incidence of metastatic
breast cancer. As the breast cancer incidence data analyzed
by Welch et al. started in 1975 and screening in the USA dis-
seminated shortly thereafter, limited data were available
from a prescreening period. However, long-term breast can-
cer incidence data from Rochester, Minnesota [2], from Kaiser
Permanente, Portland [3], and from the Connecticut Tumor
Registry [4], showed prescreening, cohort-related increases in
the breast cancer incidence. Based on long-term prescreen-
ing breast cancer incidence data from other countries (for
instance Denmark, see section below), it seems likely that the
US prescreening cohort trends would have continued also
after the start of screening.
Second, screening implies a change in time of diagnosis
and therefore a change in the incidence pattern. At the start
of screening, a prevalence peak is observed, during screening
an artificial aging, and when the women have exited screen-
ing a compensatory dip will be seen in the incidence [5]. If it
takes 2 years to carry out the prevalence screen, around a
100% increase in incidence will be observed during the
period [6]. Screening started gradually in the USA, with 17%
(aged 50þ) in 1978 having had a mammogram to 74% in
1992 (aged 40þ) [7]. This means that in the USA, the preva-
lence peak is spread out over a long time interval, and that
very long time will pass before the compensatory dip
becomes visible at the population level. It is therefore ques-
tionable when Welch et al. attribute the observed increase in
breast cancer incidence to overdiagnosis. The use of
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